Literature DB >> 22071628

Proteasome inhibitors suppress expression of NPM and ARF proteins.

Bulbul Pandit1, Andrei L Gartel.   

Abstract

Proteasome inhibitors stabilize numerous proteins by inhibiting their degradation. Previously we have demonstrated that proteasome inhibitors thiostrepton, MG132 and bortezomib paradoxically inhibit transcriptional activity and mRNA/protein expression of FOXM1. Here we demonstrate that, in addition to FOXM1, the same proteasome inhibitors also decrease mRNA and protein expression of NPM and ARF genes. These data suggest that proteasome inhibitors may suppress gene expression by stabilizing their transcriptional inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071628      PMCID: PMC3266112          DOI: 10.4161/cc.10.22.18211

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

Review 1.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 2.  The proteasome: a suitable antineoplastic target.

Authors:  Julian Adams
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

Review 3.  Degradation of ubiquitin: the fate of the cellular reaper.

Authors:  Nitzan Shabek; Aaron Ciechanover
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

Review 4.  Protein degradation or regulation: Ub the judge.

Authors:  M Hochstrasser
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

5.  Redundancy and variation in the ubiquitin-mediated proteolytic targeting of a transcription factor.

Authors:  Eric M Rubenstein; Mark Hochstrasser
Journal:  Cell Cycle       Date:  2010-11-22       Impact factor: 4.534

6.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Authors:  Chandrashekhar Korgaonkar; Jussara Hagen; Van Tompkins; April A Frazier; Chantal Allamargot; Frederick W Quelle; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 7.  Development of the proteasome inhibitor Velcade (Bortezomib).

Authors:  Julian Adams; Michael Kauffman
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

8.  Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.

Authors:  Simone Fulda
Journal:  Oncotarget       Date:  2011-05

10.  Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.

Authors:  Nickolay Neznanov; Andrei P Komarov; Lubov Neznanova; Patricia Stanhope-Baker; Andrei V Gudkov
Journal:  Oncotarget       Date:  2011-03
View more
  3 in total

1.  Mutual Regulation of FOXM1, NPM and ARF Proteins.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  J Cancer       Date:  2015-04-28       Impact factor: 4.207

2.  MG132 inhibits the expression of PBX3 through miRNAs by targeting Argonaute2 in hepatoma cells.

Authors:  Daiyong Mou; Xiaodan Yang; Sheng Li; Wei Zhao; Meng Li; Maoji Zhao; Nasser Hadal Alotaibi; Zhiqian Zhang; Min Tang; Khalid Saad Alharbi; Joob Bahman; Syed Nasir Abbas Bukhari; Cristina Dézlla
Journal:  Saudi J Biol Sci       Date:  2020-06-16       Impact factor: 4.219

3.  Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.

Authors:  C Kao; A Chao; C L Tsai; C Y Lin; W C Chuang; H W Chen; T C Yen; T H Wang; C H Lai; H S Wang
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.